Stifel analyst Thomas Shrader weighed in on Kite Pharma (NASDAQ: KITE) after rival Juno Therapeutics has again placed the ROCKET ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE